You are here: Home: Meet The Professors Vol. 3 Issue 6 2005: CME Information
Meet The Professors: A case-based discussion on the
management of breast cancer in the adjuvant and
metastatic settings
STATEMENT OF NEED / TARGET AUDIENCE
Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results
from a plethora of ongoing clinical trials lead to the continuous emergence of new therapeutic
agents and changes in the indications for existing treatments. In order to offer optimal patient
care — including the option of clinical trial participation — the practicing medical oncologist
must be well informed of these advances. In order to incorporate research advances into developing
treatment strategies for patients, the CME program Meet The Professors utilizes case-based
discussions between community oncologists and research leaders.
LEARNING OBJECTIVES
- Critically evaluate the clinical implications of emerging clinical trial data in breast cancer
treatment and incorporate these data into a management strategy in the adjuvant,
neoadjuvant and metastatic settings.
- Counsel appropriately selected patients about the availability of ongoing clinical trials.
- Counsel postmenopausal patients with ER-positive breast cancer about the risks and
benefits of adjuvant aromatase inhibitors and of sequencing aromatase inhibitors after
tamoxifen, and counsel premenopausal women about the risks and benefits of adjuvant
ovarian suppression alone or with other endocrine interventions.
- Describe and implement an algorithm for HER2 testing and treatment of patients with
HER2-positive breast cancer in the adjuvant, neoadjuvant and metastatic settings.
- Evaluate the emerging data on various adjuvant chemotherapy approaches, including
dose-dense treatment and the use of taxanes, and explain the absolute risks and benefits of
adjuvant chemotherapy regimens to patients.
- Counsel appropriate patients with metastatic disease about selection and sequencing of
endocrine therapy and about the risks and benefits of combination versus single-agent
chemotherapy.
- Describe the computerized risk models and genetic markers to determine prognostic information
on the quantitative risk of breast cancer relapse, and when applicable, utilize these
to guide therapy decisions.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education
to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 3.25 category 1 credits
toward the AMA Physician’s Recognition Award. Each physician should claim only those credits
that he/she actually spent in the activity.
HOW TO USE THIS MONOGRAPH
This CME activity contains both audio and print components. To receive credit, the participant
should listen to the CDs or tapes and complete the evaluation form in this booklet or on our
website, www.MeetTheProfessors.com.
|